Page last updated: 2024-12-07

erythromycin 2'-acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

erythromycin 2'-acetate: prodrug of erythromycin; 2'-acetyl ester & stearate salt of erythromycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114919
CHEMBL ID2110577
CHEBI ID135882
MeSH IDM0158790

Synonyms (14)

Synonym
2'-acetylerythromycin
CHEBI:135882
992-69-8
s3q5941gcw ,
2'-acetylerythromycin a
erythromycin 2'-acetate
2'-o-acetylerythromycin a
unii-s3q5941gcw
erythromycin, 2'-acetate
CHEMBL2110577
C21595
CVBHEIRZLPKMSH-SNWVVRALSA-N
2'-o-acetyl-erythromycin a
Q27893913

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It is concluded, that food does not affect the mean bioavailability of erythromycin acistrate neither the mean rate of absorption but in some subjects the absorption from enteric coated tablets might be significantly delayed."( Effect of food on absorption and hydrolysis of erythromycin acistrate.
Haataja, H; Järvinen, A; Mattila, J; Nykänen, S, 1992
)
0.28
" Its bioavailability from hard gelatin capsules containing the drug with or without sodium bicarbonate was studied in healthy volunteers."( Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.
Marvola, M; Nokelainen, M; Nykänen, S, 1991
)
0.28
" Hence EA has a good bioavailability essential for treatment and prophylaxis of bacterial infections in dentistry."( Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
Gordin, A; Kokkonen, P; Lehtinen, R; Peltola, J; Pohto, P; Tuominen, RK; Wikberg, R, 1991
)
0.28
" The bioavailability of EA was slightly inferior to that of ES."( Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.
Hanhijärvi, H; Havas, A; Komulainen, H; Männistö, PT; Rauramaa, V; Vuorela, A, 1989
)
0.28
" In Study II, the effect of food on the bioavailability of the two EB preparations was studied after a single dose of 500 mg (2 x 250 mg enterocoated tablets) and after multiple dosing (2 x 250 mg tid)."( Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.
Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The dosage of EA was 400 mg tid and that of ES 500 mg tid."( Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema.
Antikainen, R; Brandt, H; Gordin, A; Salo, OP, 1988
)
0.27
" The dosage of EA was 400 mg tid and that of the two erythromycin base preparations 500 mg tid."( Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base.
Flygare, U; Hildén, M; Hurme, J; Järvinen, H; Leskinen, J; Pynnönen, S; Riikonen, A; Salomaa, V; Seuri, M; Wuolijoki, E, 1988
)
0.27
" The dosage of EA was 400 mg tid and that of ES 500 mg tid."( Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis.
Antikainen, R; Gordin, A; Rostila, T; Visa, K, 1988
)
0.27
" In Study II, the effect of food on the bioavailability of the two EB preparations was studied after a single dose of 500 mg (2 x 250 mg enterocoated tablets) and after multiple dosing (2 x 250 mg tid)."( Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.
Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988
)
0.27
"The drug concentration in plasma, suction skin blister fluid (SBF), urine and saliva after repeated dosage of either erythromycin acistrate (EA) or enterocoated pellets of erythromycin base (EB) was studied in young healthy volunteers with a cross-over design in two separate studies."( Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.
Haataja, H; Männistö, PT; Pohto, P; Solkinen, A; Tuominen, RK; Vuorela, A, 1988
)
0.27
"Concentrations of erythromycin and 2'-acetyl erythromycin were analysed in serum or plasma and tonsil tissue after repeated dosage of erythromycin acistrate (EA), a new erythromycin prodrug, in two separate studies in 61 young patients."( Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.
Antikainen, R; Gordin, A; Haataja, H; Männistö, PT; Savolainen, S; Tuominen, RK; Ylikoski, J, 1988
)
0.27
" The dosage of EA was 400 mg tid and that of EB 500 mg tid, and the treatment period ranged from seven to 14 days."( Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
Antikainen, R; Gordin, A; Hulmi, S; Kalima, S; Mäkelä, P, 1988
)
0.27
" The dosage of EA was 400 mg tid and that of EB 500 mg tid."( Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts.
Antikainen, R; Gordin, A; Salmi, HA, 1988
)
0.27
" Due to prolonged half-life it is more suitable for twice daily dosing than the conventional erythromycin preparations."( Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia.
Lehtonen, L; Wiesner, B; Wilen-Rosenqvist, G, 1993
)
0.29
" endometrium, myometrium, ovary and Fallopian tube, as well as in plasma, were determined after oral dosing of erythromycin acistrate (EA, CAS 96128-89-1), a erythromycin prodrug."( Erythromycin and 2'-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate.
Karhunen, M; Kokkonen, P; Lehtonen, L; Tuominen, R; Wikberg, R, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoglycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (57.69)18.7374
1990's10 (38.46)18.2507
2000's1 (3.85)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.66 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (51.85%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (48.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]